文献速递主动脉疾病

ARISE研究:新型覆膜支架治疗升主动脉夹层的首次人体评估

ARISE: First-In-Human Evaluation of a Novel Stent Graft to Treat Ascending Aortic Dissection.
PubMed 文献 · J Endovasc Ther · 2022-05-19

ARISE是一项前瞻性、多中心、非随机、单臂早期可行性研究,评估新型GORE®升主动脉覆膜支架治疗高手术风险升主动脉夹层患者的早期可行性。19例患者(平均年龄75.7岁)接受经股动脉入路支架置入,30天全因死亡率为15.8%,主要不良心脑血管事件发生5例,结果令人鼓舞。

要点

  • 30天全因死亡率为15.8%(3/19),致残性卒中和心肌梗死各1例(5.3%)。
  • 30天主要不良心脑血管事件发生5例,包括死亡、致残性卒中和心肌梗死。

核心结论

  • ARISE早期可行性研究显示,使用特定升主动脉覆膜支架治疗升主动脉夹层的结果令人鼓舞。

研究设计与样本

  • 前瞻性、多中心、非随机、单臂早期可行性研究,在美国9个中心中的7个中心入组,纳入基于计算机断层扫描成像具有合适解剖条件的高手术风险患者。
  • 共纳入19例患者,平均年龄75.7岁(范围47-91),女性11例(57.9%)。
  • 器械在透视引导下经股动脉递送,主要终点为30天全因死亡率,次要终点包括30天、6个月和12个月的主要不良心脑血管事件(MACCE)。

主要发现

  • 10例(52.6%)为DeBakey I型,其余为II型;16例(84.2%)为急性。
  • 入路方式:经皮7/19(36.8%),经股动脉10/19(52.6%),髂动脉 conduit 2/19(10.5%);所有病例均完成递送和释放。
  • 中位手术时间154分钟(范围52-392),中位造影剂用量111 mL(范围75-200)。
  • 30天MACCE发生5例,包括死亡3/19(15.8%)、致残性卒中1/19(5.3%)和心肌梗死1/19(5.3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Operative mortality for type A aortic dissection is still 10-20% at centers of excellence. Additionally, 10-20% are not considered as viable candidates for open surgical repair and not offered life-saving emergency surgery. ARISE is a multicenter investigation evaluating the novel GORE® Ascending Stent Graft (ASG; Flagstaff, AZ). OBJECTIVE: The purpose of this study is to assess early feasibility of using these investigational devices to treat ascending aortic dissection. METHODS: This a prospective, multicenter, non-randomized, single-arm study that enrolls patients at high surgical risk with appropriate anatomical requirements based on computed tomography imaging at 7 of 9 US sites. Devices are delivered transfemorally under fluoroscopic guidance. Primary endpoint is all-cause mortality at 30 days. Secondary endpoints include major adverse cardiovascular and cerebrovascular events (MACCE) at 30 days, 6 months, and 12 months. RESULTS: Nineteen patients were enrolled with a mean age of 75.7 years (range 47-91) and 11 (57.9%) were female. Ten (52.6%) had DeBakey type I disease, and the rest were type II. Sixteen (84.2%) of the patients were acute. Patients were treated with safe access, (7/19 (36.8%) percutaneous, 10/19 (52.6%) transfemoral, 2/19 (10.5%) iliac conduit), delivery, and deployment completed in all cases. Median procedure time was 154 mins (range 52-392) and median contrast used was 111 mL (range 75-200). MACCE at 30 days occurred in 5 patients including mortality 3/19 (15.8%), disabling stroke in 1/19 (5.3%), and myocardial infarction in 1/19 (5.3%). CONCLUSION: Results from the ARISE early feasibility study of a specific ascending stent graft device to treat ascending aortic dissection are promising.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Roselli EE, Atkins MD, Brinkman W, et al. ARISE: First-In-Human Evaluation of a Novel Stent Graft to Treat Ascending Aortic Dissection. J Endovasc Ther. 2022. PMID: 35587698. doi:10.1177/15266028221095018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。